Thaci, D., Gordon , K. ., Gooderham, M., Strober , B., Korman, N., Banerjee, S., Banerjee, S., Colston, E., Kim, J., Throup, J., & Morita, A. (2021). Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. SKIN The Journal of Cutaneous Medicine, 5(6), s37.